Form D · Pharmaceuticals
TITAN PHARMACEUTICALS INC
San Francisco, CA · CIK 0000910267
Offering snapshot reported Feb 7, 2022 · SEC filing
- Reported sold
- $1.52M Offering amount: $7.02M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 4, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 7, 2022 | Initial | $1,520,669 | No comparison | 1 | SEC filing |
| Jan 21, 2021 | Initial | $9,673,750 | No comparison | 7 | SEC filing |
| Jan 9, 2020 | Initial | $2,175,000 | No comparison | 5 | SEC filing |
| Aug 19, 2019 | Initial | $2,125,512 | No comparison | 1 | SEC filing |
| Jan 4, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $106K
- Finders' fees
- $0
- Form D file number
- 021-432660
Offering amount represents 1,289,796 Pre-Funded Warrants and 4,664,038 Placement Warrants at a combined purchase price of $1.179 per warrant. Amount sold represents 1,289,796 Pre-Funded warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLC | 120708 |
Source: Form D, filed Feb 7, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joseph A. Akers | Director |
| Katherine Beebe | Executive |
| Sunil Bhonsle | Director, Executive |
| Katherine Beebe De Varney | Director, Executive |
| Dane Hallberg | Executive |
| Rajinder A. Kumar | Director |
| M. David Mc Farlane | Director |
| James R. Mc Nab, Jr. | Director |
| Marc Rubin | Director, Executive |
| Scott A. Smith | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
400 Oyster Point Blvd Suite 505
San Francisco, CA, 94080
San Francisco, CA, 94080